LLY

Eli Lilly and Company

  • sector: Healthcare
  • exchange: NYSE
  • in 4 Arithmos indices

Indices that include LLY 4/4

sort
weight≥ 0.0%
alongside
  1. #1

    Extreme Growth Leaders Index – 10Y Momentum-Weighted

    LLY · 1.82%NVDAAMDMULRCX+5 more

    Tenth-place with 1,027% return (10.27x), driven by blockbuster diabetes/obesity drugs and 43% YoY revenue growth. Receives minimum 2% allocation as the only non-tech holding, providing modest sector diversification at the tail.

    CAGR
    59.4%
    Sharpe
    1.07
    max DD
    -61.6%
  2. #2

    Maximum Growth Leaders Index — Growth×Momentum Weighted

    LLY · 10.00%MUNVDAPLTRAMD+7 more

    Pharmaceutical growth leader with 56% revenue growth from blockbuster GLP-1 drugs, 83% gross margin, and 35% 1Y return. Weighted at 11% as top non-tech growth story with exceptional ROE of 107%.

    CAGR
    44.6%
    Sharpe
    1.08
    max DD
    -43.8%
  3. #3

    Defensive US Core 20

    LLY · 7.14%WMTUNHCOSTPG+9 more

    Eli Lilly and Company — Healthcare.

    CAGR
    14.1%
    Sharpe
    0.84
    max DD
    -25.9%
  4. #4

    GLP-1 Obesity Boom Index

    LLY · 25.00%NVOVKTXAMGNZBH+3 more

    Mounjaro/Zepbound dominance and orforglipron oral pipeline.

    CAGR
    –
    Sharpe
    –
    max DD
    –

Build your own index that includes LLY.

Write a plain-English prompt, get transparent rules and a 10-year backtest.

start a prompt →

Performance figures are simulated backtests, not live returns. Past performance does not predict future results. Arithmos is a research and data tool, not investment advice.

/home·/markets·/feed·/leaderboard·/sharpe·/blog·/pricing·/about·/vacancies·/contact·/links·/terms
⚠Investment research & data tool · not investment advice · not a regulated broker or advisor · past performance does not guarantee future results.